Search clinical trials for: Epidermal Growth Factor Receptor Variant III

Total 66584 results

Beijing Tsinghua Chang Gung Hospital
Beijing DCTY® Biotech Co.,Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Recurrent Glioblastoma
Amgen

Completed

AMG 595 First-in-Human in Recurrent Gliomas

Glioblastoma Multiforme | Advanced Malignant Glioma | Anaplastic Astrocytomas

United States, Australia
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Germany, Taiwan, Australia, China, Korea, Republic of
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
Institut Català d'Oncologia
Fundación Sociedad Española de Oncologia Médica; Instituto de Salud Carlos III and other collaborators

Recruiting

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)

Neoplasms | Breast Cancer | HER2-positive Breast Cancer

Spain
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Allist Pharmaceuticals, Inc.

Not yet recruiting

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD)

Non-small Cell Lung Carcinoma
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

Metastatic Colorectal Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Pfizer

Completed

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)

Breast Cancer

Austria, Bulgaria, Italy, Portugal, Romania
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Breast Neoplasms

Korea, Republic of, Germany, United States, United Kingdom, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Phili... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

Japan, Poland, United States, Australia, Belgium, Brazil, Canada, China, Colombia, Costa Rica, France, Germany, Hungary, Ireland, Israel, Korea, Republic of, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Taiwan, Ukr... and more
University of Nebraska
National Cancer Institute (NCI)

Terminated

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2-negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation (GeoMETry-III)

Carcinoma, Non-Small-Cell Lung

Belgium, Germany, Italy, France, Netherlands, Spain, Korea, Republic of, India, Brazil, Portugal
Fudan University

Completed

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Non-small-cell Lung Cancer

China
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Spanish Lung Cancer Group

Completed

Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR (EURTAC)

Non-Small Cell Lung Cancer

Spain, France, Italy
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Hoffmann-La Roche

Completed

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)

Breast Cancer

United States, Canada, Denmark, France, Italy, Poland, Portugal, Spain, United Kingdom, Norway, Germany, Mexico
Hoffmann-La Roche

Completed

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SafeHER)

Breast Neoplasms

Hungary, Italy, United Kingdom, Canada, Czechia, Bulgaria, Croatia, Dominican Republic, France, Germany, Greece, Guatemala, Hong Kong, Indonesia, Ireland, Korea, Republic of, Netherlands, Panama, Peru, Poland, Portugal, Slovakia, Spain and more
Hoffmann-La Roche

Terminated

A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC) (TRAXHER2)

Breast Cancer | Gastric Cancer

Italy, Argentina, Canada, France, Greece, Portugal, Slovakia, Brazil, Russian Federation, Spain, Germany, Serbia
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
Hoffmann-La Roche

Completed

A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (SCHEARLY)

Breast Cancer

Italy
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Hebei Medical University

Unknown

Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

Gastroesophageal Junction Adenocarcinoma

China
National Cancer Institute (NCI)

Completed

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Glioblastoma | Brain Cancer | Malignant Glioma | Gliosarcoma

United States
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Italy, Korea, Republic of, Spain, Germany, Poland, Switzerland
Sidney Kimmel Comprehensive Cancer Center at Johns...

Completed

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

Singapore
University of Arizona
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Synta Pharmaceuticals Corp.; New York University...

Completed

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Guangdong Provincial People's Hospital

Unknown

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC (TREND)

Non-small Cell Lung Cancer | Epidermal Growth Factor Receptor

China
Chinese Society of Lung Cancer
Guangdong Provincial People's Hospital

Completed

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Thoracic Neoplasms

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) (ANSWER)

Carcinoma, Non-Small-Cell Lung

China
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Epidermal Growth Factor Receptor and K-ras Mutations in Patients With Stage III Non-Small Cell Lung Cancer

Lung Cancer
AstraZeneca

Completed

A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer). (REASON)

Non Small Cell Lung Cancer

Greece
Memorial Sloan Kettering Cancer Center
Ascenta Therapeutics

Terminated

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Lung Cancer

United States
OSI Pharmaceuticals

Completed

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT)

Non-small Cell Lung Cancer

United States, Hungary, Spain, Taiwan, Korea, Republic of, Italy, United Kingdom, Canada, Australia, Belgium, Germany, Austria, Poland, Romania, Argentina, France, Czech Republic, Greece, Russian Federation
Tongji University
Sun Yat-sen University; Peking Union Medical College Hospital; RenJi Hospital; Guangdong... and other collaborators

Completed

Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)

Non-small Cell Lung Cancer

China
AstraZeneca

Completed

Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations. (IDENTIFY)

Non-Small Cell Lung Cancer | Stage IIIB/IV

Argentina
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
AstraZeneca

Completed

First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

Pulmonary Cancer

Korea, Republic of
Fudan University

Not yet recruiting

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Advanced Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer

China

Search clinical trials for: Epidermal Growth Factor Receptor Variant III

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations